Sales flag Cyberonics struggles with coverage
This article was originally published in Clinica
Executive Summary
A year on after successfully clinching FDA approval to market its vagus nerve stimulation (VNS) therapy for treatment-resistant depression (TRD), Cyberonics is struggling to obtain the all-important insurance coverage for its device.